OTLK Outlook Therapeutics

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
EN
07/10/2020

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was c...

March 5, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Expands European Footprint with Exclusive Commerc...

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasda...

February 19, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial ...

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Submits Type A Meeting Request to FDA Following C...

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company’s Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of ...

February 11, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corp...

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s tw...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch